Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 9/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761680 | 0.87 | DRD3 (0.36) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL12094076 | 0.82 | RAB9A (0.48) | NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL12094075 | 0.82 | NPSR1 (0.42) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL10132074 | 0.80 | SMN1; SMN2 (0.52) | MEN1KMT2ANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL4761690 | 0.80 | BTK (0.42) | KMT2ADRD3DRD2HTR2AHTR1A | |
| SCHEMBL25030885 | 0.79 | NPSR1 (0.40) | MEN1KMT2ADRD3DRD2HTR2A | |
| SCHEMBL26062862 | 0.79 | NPSR1 (0.40) | MEN1KMT2ADRD3DRD2HTR2A | |
| SCHEMBL23135471 | 0.78 | NPSR1 (0.53) | MEN1KMT2ADRD3DRD2HTR2A | |
| SCHEMBL25029638 | 0.77 | MME (0.40) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL10148018 | 0.76 | MAPT (0.40) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120123065-A1 | Hydrolytically Stable Maleimide-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-8106131-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | MEN1 70/4885KMT2A 984/4885DRD3 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.